Experts Advocate for Expanded Treatment of Hepatitis B to Save Lives

Recent publications in The Lancet Gastroenterology & Hepatology emphasize the urgent need to broaden hepatitis B treatment guidelines. Scientists argue that current treatment criteria significantly underestimate the number of individuals who could benefit from antiviral medications. Data shows that hepatitis B (HBV) claims over 3,000 lives daily worldwide, often leading to liver failure or liver cancer if untreated. Remarkably, only less than 3% of those infected currently receive treatment, despite the fact that early intervention can slow disease progression and reduce transmission.

The research highlights that hepatitis B drugs are safe, effective, and affordable, yet underutilized. Dr. John Tavis from Saint Louis University states, "These medications are effective but underused. Early treatment could drastically decrease the rates of liver cancer and death. By expanding treatment eligibility, we can improve quality of life and prevent millions of deaths."

Hepatitis B often passes from mother to child, with many mothers unaware of their infection, leading to vertical transmission. Social stigma and lack of awareness further hinder effective management, especially in high-prevalence regions. Tavis emphasizes the social burden, noting that many hide their diagnosis due to fear of unemployment or community ostracism, despite the virus not spreading through casual contact.

The studies suggest that expanding treatment to include more individuals could cut liver cancer incidence by two-thirds, potentially saving countless lives over the next few decades. Researchers advocate for a paradigm shift in how hepatitis B is managed, urging earlier intervention to mitigate long-term liver damage and disease outcomes.

The articles also underscore the importance of considering patient and public health perspectives, including emotional, mental, and social impacts, when updating guidelines. Overall, the consensus among experts is that delaying treatment only prolongs suffering and increases preventable mortality, making a compelling case for policy reform in hepatitis B management.

Source: https://medicalxpress.com/news/2025-07-people-hepatitis-experts.html